Recent Quotes

CymaBay Therapeutics Inc is a part of the healthcare sector based in the United States. Its main business involves the development of therapeutics such as Arhalofenate, MBX-8025, and MBX-2982. These drugs are intended to treat serious metabolic disorders. Arhalofenate is used to treat gout, MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes and MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta.

Earnings

Q1 2021		Est.		Actual		Surprise
EPS		-0.240		-0.250		-0.0100
REV				0

Q4 2020		Est.		Actual		Surprise
EPS		-0.200		-0.230		-0.0300
REV				0

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Related Companies

Ticker	Company	Price	Change	Chg %		Mkt Cap
CBAY	CymaBay Therapeutics	4.63	-0.29	-5.89%		319.5M

CymaBay Therapeutics Frequently Asked Questions

How do I buy CymaBay Therapeutics (CBAY) stock?

You can purchase shares of CymaBay Therapeutics (NASDAQ: CBAY) through any online brokerage.

View our list of the best stock brokerages.

Who are CymaBay Therapeutics's (CBAY) competitors?

Other companies in CymaBay Therapeutics’s space includes: Iterum Therapeutics (NASDAQ:ITRM), Verona Pharma (NASDAQ:VRNA), WAVE Life Sciences (NASDAQ:WVE), BioDelivery Sciences Intl (NASDAQ:BDSI) and Xeris Pharmaceuticals (NASDAQ:XERS).

What is the target price for CymaBay Therapeutics (CBAY) stock?

The latest price target for CymaBay Therapeutics (NASDAQ: CBAY) was reported by JonesTrading on June 14, 2021. The analyst firm set a price target for 8.00 expecting CBAY to rise to within 12 months (a possible 72.79% upside). 7 analyst firms have reported ratings in the last year.

Current Stock Price for CymaBay Therapeutics (CBAY)?

The stock price for CymaBay Therapeutics (NASDAQ: CBAY) is $4.63 last updated Fri Jun 18 2021 20:00:03 GMT+0000 (Coordinated Universal Time).

Does CymaBay Therapeutics (CBAY) pay a dividend?

There are no upcoming dividends for CymaBay Therapeutics.

When is CymaBay Therapeutics (NASDAQ:CBAY) reporting earnings?

CymaBay Therapeutics’s Q2 earnings are confirmed for after-market on August 9, 2021.

Is CymaBay Therapeutics (CBAY) going to split?

There is no upcoming split for CymaBay Therapeutics.

What sector and industry does CymaBay Therapeutics (CBAY) operate in?

CymaBay Therapeutics is in the Consumer Discretionary sector and Multiline Retail industry. They are listed on the NASDAQ.